EPI-506 (developed by Essa Pharma) is an experimental compound in phase I/II development for prostate cancer.[1] It is the successor of EPI-001 and targets the N-terminal domain of the androgen receptor. This mechanism of action is believed to allow the drug to block signaling from the androgen receptor and its splice variants.[2][3]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
Use <references />, or <references group="..." />
|
|
| Androgens |
|
| Antiandrogens |
| Antagonists |
|
| Enzyme inhibitors |
|
| Antigonadotropins |
- Anabolic steroids (e.g., nandrolone, oxandrolone)
- Estrogens (e.g., estradiol)
- GnRH agonists (e.g., leuprorelin)
- GnRH antagonists (e.g., cetrorelix)
- Progestogens (incl. allylestrenol, chlormadinone acetate, cyproterone acetate, delmadinone acetate, dydrogesterone, medroxyprogesterone acetate, megestrol acetate, nomegestrol acetate, norethisterone acetate, progesterone, spironolactone)
|
|
|
|
|
|
| Description |
|
| Disease |
|
| Treatment |
|
|
|
|
Receptor
(ligands) |
|
| Enzyme |
|
| Others |
|
Precursors/prohormones
|
|
|
Indirect
|
- Antigonadotropins (e.g., estrogens, progestogens, prolactin)
- GnRH agonists (e,g, GnRH, leuprorelin)
- GnRH antagonists (e.g., cetrorelix)
- Gonadotropins (e.g., FSH, hCG, LH)
- Kisspeptin
- Plasma proteins (ABP, albumin, SHBG)
|
|
|
|
<templatestyles src="Asbox/styles.css"></templatestyles>
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
